



October 2016

TPM[®] : World leading delivery technology

Non-Confidential Presentation

www.phosphagenics.com
(ASX : POH)



Safe Harbour Statement

This presentation, and any representations made before, during or after the presentation, may include forward-looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited to: (1) the safety or efficacy of, or potential applications for, Phosphagenics' TPM[®] platform technology; (2) the strength of Phosphagenics' intellectual property; (3) the timelines for Phosphagenics' clinical trials and regulatory processes for its different products; (4) the scalability and efficiency of manufacturing processes; (5) revenue projections, market share expectations, share price expectations and capital requirements.

Actual results may differ from the expectations expressed in these forward-looking statements, and the differences may be material (whether positive or negative). The risks that may cause Phosphagenics' actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, include but are not limited to: (1) risks inherent in the development, approval and commercialisation of potential products; (2) uncertainty of clinical trial results or regulatory approvals or clearances; (3) changes to market trends or government laws or regulations; (4) the potential need for future capital; (5) dependence upon collaborators; and (6) protection of intellectual property rights, among others. Accordingly, you should not place undue reliance on these forward-looking statements.



PHOSPHAGENICS

An Innovative Biotechnology Company Headquartered in Australia

Board of Directors:

Peter Lankau (Chair & Independent Director)

Ross Murdoch (CEO & Managing Director)

Geert Cauwenbergh (Independent Director)

David Segal (Independent Director)

Greg Collier (Independent Director)

Key Statistics:

ASX/OTCQX Code	POH/PPGNY (listed 2004)
Headquarters	Melbourne, Australia
Employees	18
Shares	~1.3 billion
Cash.	~\$10M (Jun 2016)
Annual Revenue	~\$2.3M (2015)
Market Cap	~A\$40M (A\$3.1c/share)

Key Management Personnel:

Dr Ross Murdoch (CEO & Managing Director)

Dr Paul Gavin (CSO)


Ms Anna Legg (CFO & Co. Secretary)

Dr Alex Stojanovic (VP, BD & Commercial)

Dr Roksan Libinaki (GM, Animal Health & Nutrition)


Mr Greg Moses (GM, Operations and Production)

Share Price Performance:



The TPM[®] Technology

- TPM[®] stands for “Tocopheryl Phosphate Mixture”
- TPM[®] is comprised of a unique proprietary blend of 2 phosphorylated Vitamin E derivatives
- TPM[®] is manufactured by Phosphagenics in Australia
- TPM[®] is protected by strong patent portfolio of over 100 patents in 14 Patent families
- TPM[®] has application across Human Health, Animal Health and Personal Care
- TPM[®] self assembles into nanoparticles that encapsulate drugs and nutrients
 1. Enhancing absorption into the skin
 2. Increasing oral bioavailability
 3. Increasing solubility & stability in injectable dosage forms
- TPM[®] can deliver small and large molecules
- TPM[®] is very well tolerated and has USA GRAS status ★



Phosphagenics is structured to optimise Business Focus and Cross-Business Synergy

“...leverages TPM[®]’s unique properties and broad patent portfolio across multiple lucrative markets.”



“...sharing knowledge, data and expertise reduces development risk, time and cost.”

TPM[®] is already in over 100 marketed products*

Human Health, Animal Health & Wellbeing



NOVARTIS



la prairie
SWITZERLAND



AHAVA
ACTIVE DEADSEA MINERALS



Kimberly-Clark
PROFESSIONAL[®]



BORGHESE



Murad



RevitaLash[®]
COSMETICS



ULTRACEUTICALS
REAL SKINCARE • REAL RESULTS

ASHLAND



Dr Dennis Gross SKINCARE

LE MËTIER DE BEAUTÉ

The Human Health pipeline has multiple innovative assets at various stages of development

Product	Formulation	Therapeutic Area	Partner	Research	Development	Marketed
Diclofenac	Gel	Pain (NSAID)	NOVARTIS THEMIS	★		17 Countries
Oxycodone	Patch	Pain (opioid)	TERUMO	★		Option for Japan
Oxymorphone	Patch	Pain (opioid)	TERUMO	★		Option for Japan
Daptomycin	Injectable	Antibiotic	Mylan	★		
Propofol	Injectable	Anesthetic	TERUMO			Global
2 additional products*	Other	Pain	TERUMO			Global
5 additional products*	Injectable	Assorted				

■ Partnered
 ■ Not Partnered
 ■ Option pending
 ★ Clinical POP achieved
 * undisclosed product

Voveran[®] (TPM[®]/Diclofenac gel) was launched by Novartis in India in 2014. *Now licensed across 17 countries.*

NOVARTIS

What is TPM?

- A new technology from Phosphagenics, Australia
- An ultra-flexible drug delivery system that can squeeze between skin cells
- No irritation or skin damage

Diclofenac Gel BP
New Voveran TPM gel
 More Penetration for Deeper Relief

TPM™ is a proprietary trademark of Phosphagenics, Australia.

TPM[®]/Diclofenac gel is marketed by two companies:

- Novartis
- Themis Medicare

Demonstrated to:

- outperformed the existing gold standard
- delivered more diclofenac

Phosphagenics gains revenue through both:

- Sales of TPM[®] for manufacture (\$211,000 in 2015)
- Royalties on sales (6-12%)

Now licensed across 17 countries with negotiations ongoing to further expand market.

More Penetration for Deeper Relief

Back & Muscles, Neck & Shoulders, Knees & Joints, Sprains & Strains

The Original Diclofenac with TPM technology for Deeper Pain Relief

Diclofenac Gel BP
New Voveran TPM gel
 30g
 वोवेरान-टीपीएम-जेल

NOVARTIS

Diclofenac Gel BP
New Voveran TPM gel
 30g

Diclofenac Gel BP
New Voveran TPM gel
 30g

Composition:
 Diclofenac Diethylamine BP 1.16% w/w
 Equivalent to Diclofenac Sodium BP 1% w/w in a gel

Dosage: As directed by the physician
 Store in a cool dry place.
 Do not allow to freeze.
 Store in original packaging.
 Keep out of reach and sight of children.
 Keep the tube tightly closed after use.
 Protect from light.
 Mfg. Lic. No.

Manufactured by
 Themis Medicare
 at Komwell Biopharma Pvt. Ltd., 34th K.M.,
 Tumkur Road, T. Begur, Helemangala,
 Bangalore Rural 562 123, India.

Marketed by
 Novartis India Limited
 Sandz House, Shivajinagar Estate,
 Worli, Mumbai-400 016, India.

WARNING: FOR HUMAN USE ONLY. NOT FOR VETERINARY USE. DO NOT USE AFTER EXPIRY DATE.


030000000000000000

The Opioid Market is very large with unmet needs that present real opportunities for our TPM[®] patch technology

US\$8 billion Opioid Market (USA)

- ✓ Extended Release (ER) opioids account for 70% of the market by revenue (\$6B)
- ✓ Oxycodone and oxymorphone account for 50% of all ER opioid revenues (\$3B) (despite serious PK and abuse liabilities)
- ✓ Transdermal opioids (buprenorphine and fentanyl) account for 25% of all ER opioid revenues (\$1.5B)



Opioid Sales 2013
(US\$ millions)



Transdermal has clear advantages over oral delivery: Our TPM[®] Patches deliver the desired Profile.

Ideal

Actual



Multiple pills vs. single patch




TPM[®] Opioid patches: “World firsts”

Transdermal Oxymorphone & Oxycodone Patches

Each delivering pain relief differently– one systemically - one locally




TPM[®]:Oxymorphone
Blocks Pain via
Central Nervous System



Blood circulation

Phase 1/2 POP
Undergoing further patch formulation

TPM[®]:Oxycodone
Blocks Pain Locally



Phase 2

We target considerable newsflow over the next 12 months

Business	Milestones	Timing
Human	1. <i>Initial results for TPM[®]/Oxycodone Patch Phase 2a trial</i>	<i>Announced 1Q'16</i>
	2. <i>Options (2 patches) and R&D Alliance deal (4 other products) with Terumo</i>	<i>Announced 2Q'16</i>
	3. <i>R&D Feasibility Agreement completed for new projects with Terumo.</i>	<i>Complete 3Q'16</i>
	4. Reformulation candidates of TPM[®]/Oxymorphone Patch - progression	4Q'16
	5. Dev. & License Agreement - “Opioid Patch” with Terumo	2H'16
	6. Multiple additional Business Development outcomes	4Q'16
Legal	1. ProPhase Arbitration Decision	4Q'16
	2. Mylan Arbitration Formal Hearing	2H'17
Animal	1. <i>Results for 1st Swine FCR trial (weaners to 20kg)</i>	<i>Announced 1Q'16</i>
	2. <i>Cattle program initiates</i>	<i>Complete 3Q'16</i>
	3. First results for Poultry FCR program	4Q'16
Personal Care	1. Sale of BioElixia[®] brand (dependent on ProPhase Arbitration)	4Q'16

Phosphagenics is a compelling investment opportunity

- ✓ ~\$10M cash and receivables (*Jun'16*) (~\$2M R&D Tax Incentive - 4Q'16)
- ✓ A\$2M+ annual revenues from TPM[®] and Vital ET[®] (*2015*) Tax losses >\$100M.
- ✓ Significant value-adding milestones expected over last Qtr 2016/ 1H'17
- ✓ TPM[®] technology validated through partnerships across all 3 businesses.
High interest in future business development opportunities
- ✓ Multiple commercialized products and a portfolio including “World first” transdermal Opioid patches, gels and injectables.
- ✓ Attractive valuation: Share price/value disparity. Substantial upside potential.
- ✓ Management/Board with strong industry experience.
- ✓ Focus is on shorter-term, value-adding endpoints: partnerships and revenue

“...we believe that Phosphagenics is substantially undervalued ... the Company's current total value should be A\$80-100M, or 8.5c per share...(there is) substantial upside ...”

M.Wijma, Chief Research Analyst, Van Leeuwenhoeck Research, September 2015

www.phosphagenics.com



Melbourne Office

11 Duerdin St
Clayton VIC 3168
Australia
Tel: +61 3 95651119
Email: info@phosphagenics.com

Investor Relations Questions

Kyahn Williamson
WE Buchan
Tel: +61 3 9866 4722/+61 401 018 828
Email: kwilliamson@buchanwe.com.au

Dr Ross Murdoch, CEO & Managing Director
rmurdoch@phosphagenics.com

Dr Paul Gavin, CSO
pgavin@phosphagenics.com